NASDAQ:AGRX - Agile Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.48 -0.08 (-5.13 %) (As of 03/24/2019 04:00 PM ET)Previous Close$1.48Today's Range$1.45 - $1.5752-Week Range$0.23 - $3.00Volume414,069 shsAverage Volume934,520 shsMarket Capitalization$63.95 millionP/E Ratio-2.55Dividend YieldN/ABeta0.36 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey. Receive AGRX News and Ratings via Email Sign-up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGRX Previous Symbol CUSIPN/A CIK1261249 Webwww.agiletherapeutics.com Phone609-683-1880Debt Debt-to-Equity RatioN/A Current Ratio3.81 Quick Ratio3.81Price-To-Earnings Trailing P/E Ratio-2.55 Forward P/E Ratio-3.22 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book2.51Profitability EPS (Most Recent Fiscal Year)($0.58) Net Income$-19,780,000.00 Net MarginsN/A Return on Equity-80.91% Return on Assets-60.73%Miscellaneous Employees13 Outstanding Shares43,210,000Market Cap$63.95 million Next Earnings Date5/6/2019 (Estimated) OptionableOptionable Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions What is Agile Therapeutics' stock symbol? Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX." How were Agile Therapeutics' earnings last quarter? Agile Therapeutics Inc (NASDAQ:AGRX) issued its quarterly earnings data on Tuesday, March, 12th. The specialty pharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.04. View Agile Therapeutics' Earnings History. When is Agile Therapeutics' next earnings date? Agile Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May 6th 2019. View Earnings Estimates for Agile Therapeutics. What price target have analysts set for AGRX? 3 brokerages have issued 1-year price targets for Agile Therapeutics' stock. Their predictions range from $3.00 to $4.00. On average, they expect Agile Therapeutics' stock price to reach $3.3333 in the next twelve months. This suggests a possible upside of 125.2% from the stock's current price. View Analyst Price Targets for Agile Therapeutics. What is the consensus analysts' recommendation for Agile Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agile Therapeutics. What are Wall Street analysts saying about Agile Therapeutics stock? Here are some recent quotes from research analysts about Agile Therapeutics stock: 1. Maxim Group analysts commented, "Agile Therapeutics announced topline results from its comparative adhesion wear study of Twirla vs. Xulane (generic Otho-Evra). Twirla met its primary endpoint of non-inferiority to Xulane, which the FDA considers to have acceptable adhesion for a patch contraceptive. These results will be used to answer FDA adhesion questions from the 2017 CRL and will be included in the NDA package." (2/11/2019) 2. HC Wainwright analysts commented, "We don’t think this should even be required, as Twirla is a different product than Xulane/Ortho Evra, not a generic copy, so its benefit-risk profile—which we think is better—should stand on its own merits. Nevertheless, the minutes were consistent with our expectation for a straightforward two-week crossover study (one week on each patch) to show that Twirla adhesion is non-inferior (NI) to Xulane. The company has not disclosed the specific NI margin that the agency is requiring, but the planned sample size of only n=80 suggests to us that the FDA has given them some NI breathing room. We are confident in success based on Phase 3 adhesion data (more below). Agile already had the study teed up and ready to go, and has immediately initiated it with a dermatology-specialized CRO, TKL Research." (1/11/2019) Has Agile Therapeutics been receiving favorable news coverage? News stories about AGRX stock have trended neutral this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Agile Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the company's share price in the immediate future. Are investors shorting Agile Therapeutics? Agile Therapeutics saw a decline in short interest in February. As of February 28th, there was short interest totalling 844,663 shares, a decline of 24.9% from the February 15th total of 1,125,414 shares. Based on an average trading volume of 362,532 shares, the short-interest ratio is presently 2.3 days. Currently, 3.6% of the company's stock are sold short. View Agile Therapeutics' Current Options Chain. Who are some of Agile Therapeutics' key competitors? Some companies that are related to Agile Therapeutics include Evelo Biosciences (EVLO), Seres Therapeutics (MCRB), Aclaris Therapeutics (ACRS), Kala Pharmaceuticals (KALA), Affimed (AFMD), Calithera Biosciences (CALA), AcelRx Pharmaceuticals (ACRX), Dova Pharmaceuticals (DOVA), Xenon Pharmaceuticals (XENE), Edge Therapeutics (EDGE), Avid Bioservices (CDMO), Verastem (VSTM), Tocagen (TOCA), Cerecor (CERC) and Neptune Wellness Solutions (NEPT). What other stocks do shareholders of Agile Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include Opko Health (OPK), AcelRx Pharmaceuticals (ACRX), Novavax (NVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Trevena (TRVN), Ultra Clean (UCTT), Alibaba Group (BABA), Synergy Pharmaceuticals (SGYP) and BIOLINERX LTD/S (BLRX). Who are Agile Therapeutics' key executives? Agile Therapeutics' management team includes the folowing people: Mr. Alfred F. Altomari, Chairman & CEO (Age 60)Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62) Who are Agile Therapeutics' major shareholders? Agile Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (0.91%), Geode Capital Management LLC (0.67%), Geode Capital Management LLC (0.67%), BlackRock Inc. (0.39%) and Virtu Financial LLC (0.16%). Company insiders that own Agile Therapeutics stock include Alfred Altomari, Life Sciences Maste Perceptive and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics. Which institutional investors are selling Agile Therapeutics stock? AGRX stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Agile Therapeutics. Which institutional investors are buying Agile Therapeutics stock? AGRX stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Geode Capital Management LLC, Geode Capital Management LLC and BlackRock Inc.. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari and Renee Selman. View Insider Buying and Selling for Agile Therapeutics. How do I buy shares of Agile Therapeutics? Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Agile Therapeutics' stock price today? One share of AGRX stock can currently be purchased for approximately $1.48. How big of a company is Agile Therapeutics? Agile Therapeutics has a market capitalization of $63.95 million. The specialty pharmaceutical company earns $-19,780,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Agile Therapeutics employs 13 workers across the globe. What is Agile Therapeutics' official website? The official website for Agile Therapeutics is http://www.agiletherapeutics.com. How can I contact Agile Therapeutics? Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected] MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 336 (Vote Outperform)Underperform Votes: 205 (Vote Underperform)Total Votes: 541MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/24/2019 by MarketBeat.com StaffFeatured Article: What is a Swap?